After 3 initial monthly injections, current dosing intervals range from every 8 to 16 weeks in patients with wAMD and DME and every 8 to 12 weeks in patients with DR.

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

Overall, 2679 pregnancy-related deaths could have been prevented if the national rate was reduced to the lowest state rate.

Cytisinicline treatment significantly increased the odds of smoking cessation and reduced nicotine cravings compared with placebo. Cytisinicline significantly increased the likelihood of quitting and ...

Poor communication contributed to 24% of safety incidents in 42 studies that examined its contribution along with other causes.

“Midafternoon dosing of inhaled beclomethasone dipropionate better improved nocturnal lung function and inflammatory biomarkers compared with the alternative dosage timings without additional adrenal ...

NS-229 is an investigational selective Janus kinase 1 inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation.

HealthDay News — A senior government health researcher has announced his retirement, accusing the National Institutes of Health (NIH) of censoring his latest findings on ultra-processed food. Kevin ...

Seven recommendations developed, including use of floating immunoreactive trypsinogen cutoff over fixed cutoff.

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...